An observational study in HBV, sponsored by Yaşar Bayındır, MD. Recruiting at 16 sites in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by Yaşar Bayındır, MD · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Background/Objective: Comorbidities represent a critical risk factor in the prognosis of patients receiving immunosuppressive therapy. For patients with anti-HBc IgG positivity requiring Hepatitis B virus (HBV) prophylaxis, the long-term physiological impact of oral antivirals remains a concern. This study aims to prospectively monitor bone, renal, and metabolic dysfunctions associated with oral antiviral use and other systemic risk factors over a long-term period.
Methods: The REANT Cohort is designed as a 4-year, multicenter prospective study. The cohort will consist of patients initiated on HBV prophylaxis due to immunosuppressive treatment. Participants will undergo regular longitudinal assessments to evaluate bone mineral density, renal filtration and tubular functions, and metabolic profiles. The interplay between antiviral therapy, baseline comorbidities, and long-term organ dysfunction will be analyzed.
Conclusion: The findings from the REANT Cohort are expected to provide robust evidence regarding the safety of long-term HBV prophylaxis and assist in the development of monitoring guidelines for immunosuppressed patients with latent HBV infection.
Patient Recruitment and Enrollment:
The patient enrollment phase for the study is scheduled to conclude on June 30, 2026. Each participating center is projected to enroll 35 patients, ensuring a balanced distribution of data across the multicenter framework. The study will be initiated simultaneously across all participating sites to maintain temporal consistency in data collection.
Electronic Case Report Form (e-CRF) and Coding:
Data will be managed through a centralized e-CRF system. To ensure systematic tracking and data integrity, the system will assign a unique center code to each participating institution.
Patient Identification and Confidentiality:
For each participant, a specific patient code will be automatically generated by the system. Following the standardized protocol of the study, the patient's Full Name must be entered into the system, formatted specifically with a hyphen between the first and last name (e.g., John-Doe). This structured nomenclature will ensure uniformity in the electronic database.
Yaşar Bayındır, MD is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The REANT Cohort is designed as a nationwide, multicenter study conducted across 14 specialized centers in Türkiye. These centers have been strategically selected to reflect a broad geographical and demographic diversity, ensuring a robust representation of the patient population receiving HBV prophylaxis.
Participating Provinces:
The study will be carried out simultaneously in the following 13 provinces (with 14 participating clinical sites):
Ankara, Sivas, İstanbul, Kocaeli, İzmir, Antalya, Adana, Gaziantep, Şanlıurfa, Diyarbakır, Samsun, Rize, Düzce
Sample Size Projection:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who take all antivirals recommended in the guidelines will be evaluated in the same group.
Also known as: Nucleoz(t)ide antivirals
Monitoring of renal function in patients receiving antivirals.
To assess the composite changes in renal function (GFR decline, proteinuria, etc) from baseline to month 48.
Time frame: Baseline to week 6, 12, 24, 48
Monitoring of bone health in patients receiving antivirals.
To assess the composite changes in bone health (Reduction in T-scores via DEXA) from baseline to month 48.
Time frame: Baseline to week 6, 12, 24, 48
Monitoring of metabolic status in patients receiving antivirals.
To assess the composite changes in metabolic status (HOMA-IR elevation, lipid profile alterations, etc) from baseline to month 48.
Time frame: Baseline to week 6, 12, 24, 48
Evaluation of liver status in the patients receiving HBV antivirals.
To evaluate changes in liver status by FIB-4 over 48 months. FIB-4 Index (Fibrosis-4 Index) is a formula that combines four different parameters to estimate the degree of liver damage. These parameters are: Age, AST (Aspartate Aminotransferase) level, ALT (Alanine Aminotransferase) level, and platelet count.
Time frame: Baseline to week 6, 12, 24, 48
Evaluation of liver damage in the patients receiving HBV antivirals.
To evaluate changes in liver status by APRI over 48 months. APRI (AST to Platelet Ratio Index) is a simpler calculation focusing on the relationship between liver enzyme elevation and the decrease in platelets often seen as liver disease progresses. Parameters Used: AST level, AST Upper Limit of Normal (ULN), Platelet Count.
Time frame: Baseline to week 6, 12, 24, 48
Evaluation of liver stiffness in the immunosuppressive patients receiving HBV antivirals for reactivation prophylaxis.
To evaluate changes in liver status by Fibroscan (if available in the center) over 48 months. FibroScan (also known as Transient Elastography) is a non-invasive medical imaging technique used to measure the stiffness of the liver.
Time frame: Baseline to week 6, 12, 24, 48
Plan to share: Yes — De-identified individual participant data collected during the trial will be made available upon reasonable request to qualified researchers for academic purposes following the publication of the primary study results.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After publication and then.
Access criteria: Data will be shared with qualified academic researchers who provide a methodologically sound proposal. To gain access, data requestors must sign a data use agreement (DUA) and provide proof of institutional review board (IRB) or ethics committee approval for their secondary analysis. The requested data must be used solely for the purposes of the approved research proposal.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Aug 2026, 5 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yaşar Bayındır, MD